Excessive vascular growth damages the macula, the part of the eye that translates light into image signals. Anti-VEGF therapy ...

US scientists have found answers to why treatment for neovascular age-related macular degeneration (AMD) -- a leading cause ...

Discover how Santen Pharmaceutical's monoclonal antibody targeting VEGF offers groundbreaking advancements in treating eye diseases and cancers.

Anti-VEGF is a common treatment for wet age-related macular degeneration (wet AMD) that involves injecting medication directly into your eye. That may sound scary or stressful, but there are steps ...

Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO, a vascular endothelial growth factor (VEGF) and ...

The ability of tumours to induce new blood-vessel formation has been a major focus of cancer research over the past few decades, and vascular endothelial growth factor (VEGF) is now known to be ...

Isarna Therapeutics today announced upcoming oral presentations at the OIS Retina Innovation Summit on May 4th and the Association for Research in Vision and Ophthalmology (ARVO) Meeting on May 7th, ...

The biological effects of VEGF are extremely dose-dependent. Loss of even a single allele results in fatal vascular defects in the embryo 2,3, whereas insufficient levels of VEGF or its VEGF 164 ...

Progress in oncology, and more recently ophthalmology, led to the development of VEGF antagonists, three of which are now approved for the treatment of wet AMD. Recent discoveries in ophthalmology ...

Back-of-the eye treatment company Opthea has taken this lore to heart, having rolled out three key opinion leaders – eye ...

I am a healthy 67-year-old female being treated with Eylea for wet age-related macular degeneration (AMD). I have just had my ...